^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    elimusertib (BAY 1895344)

    i
    Company:
    Bayer
    Drug class:
    ATR inhibitor
    Related drugs:
    Apply
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    08/25/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)
    Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (PEPN2112) (NCT05071209)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/22/2021
    Primary completion :
    09/30/2024
    Completion :
    11/22/2025
    BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3
    |
    PAX3-FOXO1 fusion
    |
    elimusertib (BAY 1895344)
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer (NCT04576091)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    07/06/2022
    Primary completion :
    11/27/2024
    Completion :
    11/27/2024
    TMB • CD8 • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • elimusertib (BAY 1895344) • Pembroria (pembrolizumab biosimilar)
    First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas (NCT03188965)
    Phase 2
    Bayer
    Completed
    Last update posted :
    10/11/2023
    Initiation :
    07/06/2017
    Primary completion :
    12/02/2022
    Completion :
    09/13/2023
    HER-2 • ER • PGR • ATM
    |
    ER positive • HR positive • HER-2 negative • PGR positive
    |
    elimusertib (BAY 1895344)
    BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors (NCT05010096)
    Phase 1b
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    05/27/2022
    Initiation :
    03/22/2022
    Primary completion :
    03/22/2022
    Completion :
    03/22/2022
    PIK3CA • BRCA1 • BRCA2 • PTEN • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    PIK3CA mutation • ATM mutation • PTEN mutation • ATM deletion • ATM expression
    |
    Aliqopa (copanlisib) • elimusertib (BAY 1895344)